anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the field of antineoplastic medicines and provides a betulinic acid analogue with the structure shown in figure (1) or solvate thereof. The definition of R1, R2, X and n is inThe invention relates to the field of antineoplastic medicines and provides a betulinic acid analogue with the structure shown in figure (1) or solvate thereof. The definition of R1, R2, X and n is inthe specification. The invention also provides the a preparation method of the betulinic acid analogue with the structure shown in figure (1) or the solvate thereof, and the applications of pharmaceu the specification. The invention also provides the a preparation method of the betulinic acid analogue with the structure shown in figure (1) or the solvate thereof, and the applications of pharmaceutical compositions containing the betulinic acid analogue or the solvate thereof and medicines using the betulinic acid analogue or the solvate thereof as the effective constituent for preparing antintical compositions containing the betulinic acid analogue or the solvate thereof and medicines using the betulinic acid analogue or the solvate thereof as the effective constituent for preparing antineoplastic medicines for treating pulmonary cancer, prostatic cancer, colon cancer, leukemia, mammary cancer, liver cancer, gastric cancer, pancreatic cancer, malignant neuroglioma, cerebral tumor, andeoplastic medicines for treating pulmonary cancer, prostatic cancer, colon cancer, leukemia, mammary cancer, liver cancer, gastric cancer, pancreatic cancer, malignant neuroglioma, cerebral tumor, andthe like. the like.
Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment. After a 8 week period participants in this arm well be offered Cogmed working memory training.
Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
It is an open-label , single group, multi-center study. At around 30 investigate sites, 500 dyslipidemic Chinese patients with coronary heart disease (CHD) or CHD risk equivalent, whose TG ≥1.70 mmol/L (150mg/dl) and \<5.65mmol/L (500mg/dl) after at least 2 month statin monotherapy with standard dose will be enrolled. After at least 2 month statin monotherapy with standard dose, patients having high TG will be recruited and given statin-fenofibrate combination therapy for 8 weeks. Several lipid parameters and safety parameters will be compared between baseline, after 4 weeks treatment and after 8 weeks treatment. Primary efficacy endpoint is the percentage of TG decrease before and after 8 weeks treatment. Secondary endpoints on efficacy are the absolute change and the percent of change on TC, LDL-C, HDL-C, apoA1, apoB and apoB/apoA1 of baseline, after 4 weeks treatment and 8 weeks treatment, absolute change and percentage of change of hsCRP from baseline to 8 weeks of treatment. Second endpoints on safety is the incidence of AE/SAE, change on CK, ALT, AST, BUN and Cr before and after treatment and the number of clinical meaningful abnormal change defined as ALT or AST \>3ULN, or CK \>10ULN, or BUN \>1.5ULN or Cr \>1.5ULN. Other Arm type is a self comparator
This study will include 40 healthy adults. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively.
Malaria-associated antigen (CRA) comprising glycoprotein is new. It is isolated from plasmodium-infected erythrocytes and can be bound to lectin which can enter into specific combination with terminal mannose. - Pref. the plasmodium strain is pref. P.falciparum, vivax, malarial or orale and the erythrocyte is human. It can be bound to the lectius Canavalia ensifolmis, lens calinaris or Pisum stirum. The CRA has a molecular wt. of 60000-70000 by polyacrylamide-SDS gel electrophoresis.
Control group injection process step; The individuals in this group were injected by following the routine IM injection procedure steps. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
Systems and methods of the present disclosure enable improved seizure detection and/or prediction using a seizure monitoring system. The system receives a data stream including wearable sensor data associated with a user, where the data stream includes electrodermal activity data and where the electrodermal activity data includes circadian rhythm-dependent amplitudes. The system receives a time associated with a seizure of the user. The system trains seizure machine learning model to identify a pre-ictal period associated with a time segment based on the circadian rhythm dependent amplitudes and the time associated with the seizure. The system deploys the seizure machine learning model to ingest a new data stream. Based on the new data stream, the seizure machine learning model predicts a seizure likelihood in a prediction period.
BACKGROUND: Memory deficits and anxiety symptoms are undesirable effects that occur in epilepsy patients. They may be associated with the pathophysiology of the disease but also with anticonvulsant therapy. Brivaracetam (BRV) is one of the newest antiseizure drugs. It acts as a ligand for synaptic vesicle glycoprotein 2A (SV2A), which may play a significant role in cognitive processes. Although BRV has a favorable safety profile, its central side effects remain unclear. Hence, this study aimed to evaluate the effect of BRV on various types of memory and anxiety in rats.
METHODS: BRV was given to adult male Wistar rats (n = 80) via gastric tube as a single dose (6 mg/kg or 20 mg/kg) or chronically (6 mg/kg). The effect of the drug on spatial memory was evaluated in the Morris water maze (MWM), fear-learning by passive avoidance (PA), and recognition memory with novel object recognition (NOR). The elevated plus maze (EPM) was used to assess anxiety-like behaviors.
RESULTS: The impact of BRV on memory is dose-dependent and mainly high doses may alter retrieval memory and fear-learning. Sub-chronic administration also impaired retrieval and spatial memory in animals. Moreover, chronic BRV may increase anxiety levels in rats but did not affect recognition memory.
CONCLUSIONS: BRV may cause transient memory deficits as well as anxiety disturbances. However, the results are varied and depend on the type of memory, used dose, and duration of administration.
At present there is no standard method for the evaluation of in vivo cuff leak and aspiration. Most of the tested techniques have major pitfalls that render their routine application infeasible. Lacking a practical and reliable marker, any possible intervention aimed at improving cuff seal and ETT performance in order to reduce VAP occurrence is going to be hindered by the inability to truly evaluate its efficacy. Radiolabeled markers are expensive, expose the patient to considerable radiological risk, and require transport to a radiological department, which would expose critically ill patients to additional risk. Dyes have the potential to give useful information about the presence of a cuff leak, but due to persistent staining of secretions, they do not allow continuous monitoring of aspiration. Amylase detection could be a good marker of aspiration, but its ability to detect aspiration is poor even when compared to pepsin. Pepsin and bile acids have the potential to detect some of the aspirations and cuff leaks that happen daily in mechanically ventilated patients, but due to their gastrointestinal nature, they do not offer any kind of information about aspiration of contaminated oropharyngeal secretions. With this research protocol, we would like to validate the use of diatom skeletons suspended in saline as a marker for determining cuff leakage and aspiration events in an ICU population and compare its efficacy in identifying aspiration events with pepsin detection. Diatoms are a major group of algae, composing the majority of phytoplankton. Their diameter is 5-15 μm on average and 1 ml of seawater usually contains about 104 diatoms. They are unicellular organisms and their main feature is that they are enclosed within a cell wall made of amorphous silica, biopolymerized in a geometric fashion that is species-dependent. At the end of their vital cycle, diatom shells deposit at the bottom of the sea. Diatom shell deposits have been found in almost every place on Earth, and are the main component of diatomaceous earth (DE). DE is an extremely fine powder composed of diatom shells that have accumulated over thousands of years. Due to its microscopical texture and inexpensive nature, it is commonly employed as a filtering media for beverages and a drying and anti-mold agent for cereals. Diatom shells compose food-grade DE in its entirety. Due to its non-crystalline, amorphous nature, it is essentially nontoxic. Our hypothesis is that administration of 10 mg of DE suspended in 10 ml of saline into the pharyngeal cavity of intubated patients will act as a reliable marker of cuff leak and aspiration in critically ill patients. Thanks to their geometric shape, diatom shells should be easily detectable in tracheal secretions when observed under a microscope. The number of diatoms-per-field observed under a fixed magnification will allow for the detection of microaspiration in a qualitative and quantitative way. The introduction of this new, safe and inexpensive marker for evaluating ETT cuff performance and for detecting aspiration will improve the design of future studies aimed at VAP prevention
BACKGROUND AND OBJECTIVE: The association of hypouricemia and hypercalciuria is rare. In 1974 a new syndrome named Hypouricemia with hypercalciuria and decreased bone density was described. Afterwards, some cases with such association were published in which the fractional excretion of urate was higher than 20ml/100ml FGR. We have analyzed a series of children who were diagnosed with hypouricemia and hypercalciuria and who were monitored. The aim of this study was to determine whether our patients could be affected by the aforementioned syndrome or be carriers of a variant of idiopathic hypercalciuria.
PATIENTS AND METHODS: Retrospective longitudinal study in which the medical records of eight patients (5V, 3M) diagnosed with hypouricemia and hypercalciuria in childhood. Clinical features at diagnosis, ultrasound and densitometric findings and selected biochemical variables were noted, with special emphasis on renal tubular handling of urate. Results were compared with 36 children with idiopathic hypercalciuria without hypouricemia (14V, 22M).
RESULTS: In the hypouricemia group baseline urate levels were 1.9 (0.3) mg/dl (range: 1.5-2) and first day urine calcium/creatinine ratio 0.27 (0.05) mg/mg (range: 0.23-0.31). In all cases fractional urate excretion was less than 20ml/100ml FGR. The z-DMO values were less than -1 in 4/8 cases. At the last follow-up only three cases still had an elevated calcium/creatinine ratio and in all of them the urates levels was greater than 2mg/dl. The z-DMO value had improved in five cases and worsened in three others. In relation to the group without hypouricemia, no differences were observed between the various parameters studied including the z-DMO value, with the exception of fractional excretion and tubular urate reabsorption although plasmatic uric acid levels were still significantly lower.
CONCLUSION: Our patients with hypercalciuria and hypouricemia would be affected by a variant of idiopathic hypercalciuria in which, due to an unknown cause, the proximal tubular reabsorption of urate is modestly reduced and improves over time. Hypouricemia with hypercalciuria and decreased bone density may not be a specific entity.
A different type of hot pack was applied in the lower back of each subject: moist heat pack (MHP) , seed pack (SP) or gel pack (GP) as directed by each manufacturer and in accordance with clinical practice for 15 minutes for 3 consecutive days. On day one, prior to the application of the pack, the initial evaluation of flexibility of the lumbar spine of each subject was recorded using Schober test. On day 3, after the application of each pack, the final evaluation of the flexibility of the lower back was performed using the same test. During the sessions, the temperature of the corporal area, the temperature of the pack and the pigmentation change of the corporal area were assessed every 5 minutes through a photographic record.The method used to assess the flexibility was the Schober Test. In order to perform the evaluation, the patient was placed in standing position with its bare feet slightly apart; two points were marked on the skin, one above the spinous apophysis S1 and another point, 10 cm above that mark. The patient performed a maximal trunk flexion without flexing the knees and the increase of the distance between the two marks was recorded. After this evaluation, the packs were applied on the lower back, wrapped in two layers of towels in order to avoid skin injuries by the heat. The temperature of the lower back and of each type of pack was recorded at minutes 0 (baseline measurement), 5, 10 and 15. Temperature was measured through a digital pyrometer at a set distance of 50 cm and it was held perpendicular to patient skin and the pack. The photographic record of the lower back of each subject, before and after each session of superficial thermotherapy, was recorded using a digital camera . The camera was placed perpendicular to the lower back, at a distance of 50 cm. The brightness of the photograph was taken into account so as not to affect the later analysis of the erythema. The erythema analysis of the lower back was performed with the freeware Picture Color Analyzer (Shizuoka, Japan; http://www.isao.com). The software measures the red color intensity of each pixel (attributing a value between 1 and 255) within the chosen area. The average red color value obtained in arbitrary units is the result of the following formula: Average red color = total red color value / (255 X number of pixels in the area).
Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
Subjects with other tumors with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
Although the data are preliminary, there are studies suggesting that mild endometrial trauma in the cycle preceding IVF increases pregnancy rates, at least in women with recurrent implantation failure. Whether endometrial biopsy could promote implantation and improve pregnancy rates in the larger population of women undergoing IVF has yet to be explored. The present study will address this question and examine the impact of endometrial biopsies on IVF outcomes in the context of a randomized controlled trial.

The optimal timing of the endometrial biopsy in the cycle preceding IVF has not been determined, but the majority of the studies have included a biopsy in the mid-luteal phase of the preceding cycle. In order to allow an adjuvant therapy to IVF that would be considered tolerable to a subject, and applicable to a large infertile women population, it was determined that a single endometrial biopsy, performed approximately 1 week prior to the start of controlled ovarian hyperstimulation (COH) in an IVF cycle, would be the simplest, most flexible, and generalizable intervention to study its effects on pregnancy rates. All other components of the IVF treatment will remain constant with approximately 8-12 days of ovarian stimulation, human chorionic gonadotrophin (HCG) trigger being administered in that time frame and oocyte retrieval occuring 36 hours later from trigger. The embryo transfer will take place either day 3 or day 5 after oocyte retrieval.
A first storage stores a first medical image, positional information in the first medical image and regional information corresponding to the positional information, respectively. A second storage stores second medical images. A display unit displays the first medical image and the second medical images stored in the second storage. A selector selects a second medical image to be associated with the first image. A specifying unit which specifies a position to be associated with the selected second medical image and a position on the displayed first medical image. An extraction unit extracts regional information associated with the specified position, based on the specified position and the positional information. A third storage stores association between the extracted positional information and the selected second medical image.
The intervention in the married male arm provided health education based on baseline findings to address gaps. Community agents and videos featuring men involved in family planning (FP), a male model supporting his wife's FP use, and a supportive husband sharing information with his wife were used. Clan leaders "Abbaa Gada" (Indigenous Oromo), religious leaders, and district FP experts also played key roles. Monthly 1-hour sessions over 6 months delivered health education messages about FP. The 374 men selected were the husbands in the intervention group, participating in household and individual-level interventions alongside their wives and attending community gatherings twice. Note: The group size for the male arm (Male Involvement group) was 374 men.
Sugammadex administration may increase the bispectral index (BIS) values during general anesthesia. The purpose of this study was to investigate the influence factors leading to increase in BIS value caused by sugammadex administration when continuous use of general anesthetics. Patients undergoing elective surgery were included in this study. After surgery was completed while the train-of-four ratio was zero, a steady-state intravenous anesthesia was maintained to keep a BIS value within the range of 40-60 for at least 5 minutes. Patients received sugammadex 2 mg.kg-1 after completed surgery. BIS values were recorded every minute and clinical signs of awaking was also noted.
INTRODUCTION: Benign prostatic hyperplasia (BPH) is a condition commonly seen among men aged over 40, significantly affecting their quality of life and typically accompanied by lower urinary tract symptoms (LUTS). Acupuncture presents a potentially effective treatment option; however, the exact effects remain uncertain. Therefore, we design this multicentre randomised trial to evaluate the efficacy and safety of electroacupuncture (EA) for relieving LUTS in men with BPH.
METHODS AND ANALYSIS: A two-arm, sham-controlled, subject-blinded and assessor-blinded trial will be conducted in 11 hospitals in China to compare EA with sham electroacupuncture (SA) in treating moderate to severe LUTS of BPH among men aged 40-80. A total of 306 eligible male patients will be recruited and assigned at a 1:1 ratio to receive either EA or SA for 24 sessions over a succession of 8 weeks, with 24 weeks of follow-up. The primary outcome will be the proportions of participants with at least 30% reduction in the International Prostate Symptom Score total score from baseline at weeks 8 and 20. All statistical analyses will be conducted in accordance with the intention-to-treat principle, and a two-tailed p value less than 0.05 will be considered statistically significant.
ETHICS AND DISSEMINATION: The trial has been approved by the institutional review board of Guang'anmen Hospital (2022-203-KY), as well as other recruitment centres. Each participant will receive the detailed information of the trial, and sign the written informed consent. The results of the trial are expected to be published in a peer-reviewed journal.
TRIAL REGISTRATION NUMBER: NCT05585450.
The invention belongs to the technical field of veterinary medicines, and in particular, relates to a Chinese herbal preparation for treating avian influenza and a preparation method therefor. The Chinese herbal preparation is prepared strictly based on the compatibility among monarch, minister, assistant, and guide. A prescription based on honey-fried herba ephedrae, almond, gypsum and liquorice is optimized by reducing the quantities of honey-fried herba ephedrae, almond, gypsum and liquorice, and by adding isatis root, cordate houttuynia, wrinkled gianthyssop herb, Chinese rhubarb, and Schizonepeta. The Chinese herbal preparation finally prepared by means of optimization has an extremely good inhibitory effect against H9N2 subtype influenza viruses, and exhibits the total effective rate of 100% in clinical application. Moreover, the preparation is a pure Chinese herbal preparation which is prepared according to a scientific and brief prescription and a simple preparation method. The Chinese herbal preparation is featured with low dose at a working concentration (greater than 100-fold dilution), low cost, no toxicity, safety, and no residue, and can ensure food safety while being used for treating and preventing the avian influenza, showing a broad market prospect.
1435892 Aluminium complexes of guaiphenesin BEECHAM GROUP Ltd 20 June 1973 [4 July 1972] 31240/72 Heading C2C The invention comprises a mixture of (a) an aluminium complex of guaiphenesin wherein the ratio of aluminium atoms to guaiphenesin molecules in which one or both of the hydroxyl hydrogen atoms have been replaced so that the hydroxyl oxygen atom has become covalently bound to an aluminium atom is approximately 2 : 3 and (b) aluminium hydroxide and/or polyoxoaluminium hydroxide. As component (a) of the mixture, especially suitable complexes of the invention have the empirical formula [Al 2 (C 10 H 12 O 4 ) 3 ] n  where n is an integer and preferably 2. The invention also comprises a solid and pharmaceutical composition comprising a mixture of a complex of aluminium and guaiphenesin and aluminium hydroxide and/or polyoxoaluminium hydroxide together with conventional pharmaceutical excipients and advantageously containing other pharmaceutically acceptable aluminium containing substances such as an aluminium oxide. The aluminium complexes of guaiphenesin may be prepared by reacting an aluminium alcoholate or polyoxo aluminium alkoxide and guaiphenesin in the presence of water. This process automatically results in the preparation of the complex in admixture with aluminium hydroxide and/or polyoxo aluminium hydroxides. By "aluminium alcoholate" is meant a compound of the empirical formula Al(OR) 3  where R is an alkyl group of 1 to 6 carbon atoms. By "polyoxo aluminium alkoxide" is meant the reaction product of the reaction between one mole of an aluminium alcoholate with two moles of water.